Assetmark Inc. Trims Holdings in Lantheus Holdings, Inc. $LNTH

Assetmark Inc. reduced its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 81.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 22,495 shares of the medical equipment provider’s stock after selling 95,805 shares during the quarter. Assetmark Inc.’s holdings in Lantheus were worth $1,706,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in LNTH. Smartleaf Asset Management LLC boosted its position in shares of Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 197 shares during the period. Parallel Advisors LLC increased its stake in shares of Lantheus by 122.6% during the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 298 shares during the period. Osterweis Capital Management Inc. acquired a new stake in Lantheus in the second quarter valued at approximately $36,000. Bessemer Group Inc. increased its position in shares of Lantheus by 221.2% in the 1st quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 354 shares during the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in Lantheus in the fourth quarter valued at $39,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

LNTH has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Lantheus in a report on Tuesday, May 26th. Citizens Jmp reiterated a “market outperform” rating and set a $115.00 target price on shares of Lantheus in a research note on Monday, June 29th. Citigroup restated an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. Mizuho upped their price objective on Lantheus from $115.00 to $120.00 and gave the company a “market outperform” rating in a research note on Wednesday, July 15th. Finally, Truist Financial increased their price objective on Lantheus from $115.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $110.43.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $104.82 on Friday. The business has a fifty day simple moving average of $103.36 and a 200-day simple moving average of $85.56. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $111.86. The company has a market cap of $6.82 billion, a P/E ratio of 25.26 and a beta of -0.06.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The firm had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. During the same period in the previous year, the firm earned $1.53 earnings per share. Lantheus’s revenue was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities research analysts forecast that Lantheus Holdings, Inc. will post 4.5 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.